ClinicalTrials.gg
CompletedNCT03405064Updated Jun 29, 2020

Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

A Phase 3 interventional study of Oral Levonadifloxacin/Linezolid Tablet and Intravenous Levonadifloxacin/Linezolid Infusion in Acute Bacterial Skin and Skin Structure Infections, sponsored by Wockhardt. Completed at 32 sites in India. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-06-29.

Sponsored by Wockhardt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
501
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a phase III, multi-center, randomized, active-comparator, study in subjects with ABSSSI. The study has two subgroups for assessment of efficacy and safety - oral subgroup 1 and IV subgroup 2. Each subgroup will comprise of two treatment arms.

Read the detailed description

Subjects willing to participate in the study and fulfilling all eligibility criteria will receive either oral therapy (subgroup 1) or IV therapy (subgroup 2). The investigator can initiate treatment with either oral or IV therapy based on clinical judgement i.e subjects who require IV therapy (like subjects with severe ABSSSI or where oral administration is not feasible).

02

Conditions studied

  • Acute Bacterial Skin and Skin Structure Infections
03

In context

Lead sponsor

Wockhardt is the lead sponsor of 39 studies on the registry; 3 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must be willing to participate in the study and provide a written
  • Subjects with ABSSSI characterized by any of the following infection types:

    1. Cellulitis/erysipelas: diffuse skin infection characterized by spreading areas of redness, edema, and/or induration
    2. Wound infection: An infection characterized by purulent drainage from a wound with surrounding redness, edema, and/or induration
    3. Major cutaneous abscess: An infection characterized by a collection of pus within the dermis or deeper that is accompanied by redness, edema, and/or induration
  • Subjects with lesion size area of at-least 75 cm2. Lesion size will be measured by the area of redness, edema, or induration
  • Subjects with suspected and/or documented evidence of Gram-positive infection

Exclusion criteria

Exclusion Criteria:

    1. ABSSSI meeting any of the following criteria:

      1. Severely impaired arterial blood supply (such that the likelihood of amputation of the infected anatomical site is likely)
      2. ABSSSI expected to require more than 10 days of antimicrobial therapy as per the discretion of the Investigator
      3. Subject with suspected or confirmed osteomyelitis or septic arthritis or gangrene
      4. ABSSSI requiring surgical intervention (except surgical incision and drainage for abscess) 2. Subjects who have received prior antibiotic therapy within past 24 hours for the treatment of current episode of ABSSSI. Following are the exceptions to this criteria:

      <!-- -->

      1. Subjects who received a single dose of a short-acting antibacterial drug within 24 hours of enrolment
      2. Subjects with evidence of clinical progression of ABSSSI while on antibacterial drug therapy after at-least 48 hours
      3. Subjects who received an antibacterial drug for surgical prophylaxis and subsequently develop ABSSSI 3. Subjects with current history or diagnosis of , positive test result for surface antigen (HBsAg) or virus (HCV) 4. Subjects with any abnormalities in pulmonary, gastrointestinal, endocrine, hepatic or renal systems
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
501 participants (actual)

Study arms

  • Experimental
    levonadifloxacin

    oral levonadifloxacin (1000 mg BID) or IV levonadifloxacin (800 mg BID)

    Drug: Oral Levonadifloxacin/Linezolid Tablet · Drug: Intravenous Levonadifloxacin/Linezolid Infusion

  • Active comparator
    linezolid

    oral linezolid (600 mg BID) or IV linezolid (600 mg BID)

    Drug: Oral Levonadifloxacin/Linezolid Tablet · Drug: Intravenous Levonadifloxacin/Linezolid Infusion

Interventions

  • DrugOral Levonadifloxacin/Linezolid Tablet

    Drug pages: Levonadifloxacin · Linezolid

    oral levonadifloxacin (1000 mg BID) or oral linezolid (600 mg BID)

  • DrugIntravenous Levonadifloxacin/Linezolid Infusion

    Drug pages: Levonadifloxacin · Linezolid

    IV levonadifloxacin (800 mg BID) or IV linezolid (600 mg BID)

06

What researchers measure

Primary outcomes

  1. The non-inferiority of oral levonadifloxacin with oral linezolid in ABSSSI by measuring the Overall Clinical Response at Test of Cure (TOC) visit in modified Intentto-treat (mITT) population in oral treatment subgroups

    Time frame: 0-14 days

  2. To establish the non-inferiority of IV levonadifloxacin with IV linezolid in ABSSSI measuring the Overall Clinical Response at Test of Cure (TOC) visit in modified Intentto-treat (mITT) population in IV treatment subgroups

    Time frame: 0-14 days

Secondary outcomes

  1. The safety of oral and IV levonadifloxacin based on adverse events reported, vital signs and physical examination findings, clinical laboratory evaluation, and ECG collected during the study.

    Time frame: 0-14 days

07

Study locations

32 sites
  • Osmania General Hospital
    Hyderabad, Andhra Pradesh 500012, India
  • Government General Hospital (Associated by Government Siddhartha Medical College)
    Vijayawada, Andhra Pradesh 520008, India
  • Sanjivani Superspeciality Hospital Pvt. Ltd.
    Ahmedabad, Gujarat 380015, India
  • Medistar Multispeciality Hospital Pvt.Ltd.
    Himmatnagar, Gujarat 383001, India
  • GMERS Medical College & General Hospital
    Vadodara, Gujarat 390021, India
  • Parul Institute of Medical Science
    Vadodara, Gujarat 391760, India
  • Victoria Hospital
    Bangalore, Karnataka 560002, India
  • Vinaya Hospital and Research Centre
    Mangalore, Karnataka 575003, India
  • Mysore Medical College and Research Institute
    Mysore, Karnataka 570001, India
  • Government Medical College
    Kozhikode, Kerala Kozhikode,, India
  • Ishwar Institute of Healthcare
    Aurangabad, Maharashtra 431002, India
  • TNMC & BYL Nair Hospital
    Mumbai, Maharashtra 400008, India
  • LTM Medical College and General Hospital
    Mumbai, Maharashtra 400022, India
  • Shree Hospital & Critical Care Centre
    Nagpur, Maharashtra 440003, India
  • Rahate Surgical Hospital
    Nagpur, Maharashtra 440008, India
  • Cresent Hospital and Heart Centre
    Nagpur, Maharashtra 440012, India
  • Indira Gandhi Government Medical College and Hospital
    Nagpur, Maharashtra 440018, India
  • B.J. Medical College and Sassoon General Hospital
    Pune, Maharashtra 411001,, India
  • Deenanath Mangeshkar Hospital & Research Centre
    Pune, Maharashtra 411004, India
  • Oyster & Pearl Hospital
    Pune, Maharashtra 411005, India
  • Noble Hospital
    Pune, Maharashtra 411013, India
  • Lifepoint Hospital
    Pune, Maharashtra 411057, India
  • Datta Meghe Institute of Medical Sciences (Deemed University) Jawaharlal Nehru Medical College
    Wardha, Maharashtra 442004, India
  • Government Medical College and Hospital
    Nagpur, Maharastra 440003, India
  • S.R. Kalla Memorial Gastro & General Hospital
    Jaipur, Rajasthan 302001, India
  • SMS Hospital
    Jaipur, Rajasthan 302004, India
  • Marudhar Hospital
    Jaipur, Rajasthan 302012, India
  • M.V. Hospital & Research Centre
    Lucknow, Uttar Pradesh 226003, India
  • Ajanta Research Centre
    Lucknow, Uttar Pradesh 2260055, India
  • KRM Hospital and Research Centre
    Lucknow, Uttar Pradesh 226010, India
  • Popular Hospital
    Varanasi, Uttar Pradesh 221009, India
  • Om Surgical & Maternity Home
    Varanasi, Uttar Pradesh 22100, India
08

References and documents

Publications

  • Bhatia A, Mastim M, Shah M, Gutte R, Joshi P, Kumbhar D, Periasamy H, Palwe SR, Chavan R, Bhagwat S, Patel M, Llorens L, Friedland HD. Efficacy and Safety of a Novel Broad-Spectrum Anti-MRSA Agent Levonadifloxacin Compared with Linezolid for Acute Bacterial Skin and Skin Structure Infections: A Phase 3, Openlabel, Randomized Study. J Assoc Physicians India. 2020 Aug;68(8):30-36. PubMed 32738837 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Sep 2018, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2017
First posted
Jan 19, 2018
StartActual
Aug 25, 2017
Primary completionActual
Sep 25, 2018
CompletionActual
Nov 30, 2018
Last update
Jun 29, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03405064
Lead sponsor
Wockhardt
Responsible party
Sponsor
First posted
Jan 19, 2018
Start date
Aug 25, 2017
Primary completion
Sep 25, 2018
Completion
Nov 30, 2018
Last update
Jun 29, 2020

Study contacts

Rakesh Chugh, MD
study director · Wockhardt

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonadifloxacin · Linezolid

Start the discussion